blue-话题@MedSci

#blue#

26篇内容 | 789人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1923736, encodeId=249e1923e36a7, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=Agendia在ASCO 2021上呈报创新性FLEX研究的数据，展示MammaPrint和BluePrint对广大类别患者群体的效用, objectType=article, longId=212564, objectId=6f2921256483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f2921256483, replyNumber=0, likeNumber=36, createdTime=2021-07-25, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f2921256483, moduleTitle=Agendia在ASCO 2021上呈报创新性FLEX研究的数据，展示MammaPrint和BluePrint对广大类别患者群体的效用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f2921256483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923735, encodeId=99a61923e35b4, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=基因治疗出岔子了？蓝鸟(Bluebird Bio)暂停LentiGlobin基因疗法1/2、3期临床研究, objectType=article, longId=207233, objectId=008b20e23326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=008b20e23326, replyNumber=0, likeNumber=28, createdTime=2022-01-10, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=008b20e23326, moduleTitle=基因治疗出岔子了？蓝鸟(Bluebird Bio)暂停LentiGlobin基因疗法1/2、3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=008b20e23326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923734, encodeId=c3d41923e3482, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=Bluebird突破性基因疗法Lenti-D申请上市！改善致死罕见病CALD患者长期生存结局, objectType=article, longId=201693, objectId=ec9320169308, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec9320169308, replyNumber=0, likeNumber=38, createdTime=2021-01-12, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec9320169308, moduleTitle=Bluebird突破性基因疗法Lenti-D申请上市！改善致死罕见病CALD患者长期生存结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec9320169308)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923732, encodeId=27fd1923e3213, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=全球改善结肠镜检查结果的口服药物Methylene Blue MMX，在欧洲获批, objectType=article, longId=199856, objectId=7f37199856fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f37199856fa, replyNumber=0, likeNumber=60, createdTime=2021-01-10, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f37199856fa, moduleTitle=全球改善结肠镜检查结果的口服药物Methylene Blue MMX，在欧洲获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f37199856fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923731, encodeId=90471923e319c, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=罗氏与Blueprint达成17亿美元协议：合作开发RET抑制剂pralsetinib治疗肺癌和甲状腺癌, objectType=article, longId=197610, objectId=85f519e610f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85f519e610f2, replyNumber=0, likeNumber=39, createdTime=2021-06-19, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85f519e610f2, moduleTitle=罗氏与Blueprint达成17亿美元协议：合作开发RET抑制剂pralsetinib治疗肺癌和甲状腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85f519e610f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923733, encodeId=3fdb1923e333f, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=吉利德Kite副总裁离职、拜耳CEO任期延长、BMS肿瘤研发首脑加入Blueprint……, objectType=article, longId=200934, objectId=8f8c200934f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8c200934f5, replyNumber=0, likeNumber=29, createdTime=2021-08-16, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8c200934f5, moduleTitle=吉利德Kite副总裁离职、拜耳CEO任期延长、BMS肿瘤研发首脑加入Blueprint……, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f8c200934f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923730, encodeId=9f6a1923e30d2, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=Blueprint的Ayvakit成为美国获批治疗罕见胃肠道间质瘤突变的靶向疗法, objectType=article, longId=186045, objectId=eda21860459a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eda21860459a, replyNumber=0, likeNumber=38, createdTime=2020-03-26, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eda21860459a, moduleTitle=Blueprint的Ayvakit成为美国获批治疗罕见胃肠道间质瘤突变的靶向疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eda21860459a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923728, encodeId=95511923e2873, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=J Endod：重复使用Reciproc Blue在根管再治疗中的循环疲劳强度, objectType=article, longId=184641, objectId=438e18464121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=438e18464121, replyNumber=0, likeNumber=25, createdTime=2020-05-02, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=438e18464121, moduleTitle=J Endod：重复使用Reciproc Blue在根管再治疗中的循环疲劳强度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=438e18464121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923729, encodeId=a4401923e29d6, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=J Endod：Reciproc和Reciproc Blue系统对弯曲根管再治疗的性能比较, objectType=article, longId=185704, objectId=825f185e04da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=825f185e04da, replyNumber=0, likeNumber=29, createdTime=2020-07-23, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=825f185e04da, moduleTitle=J Endod：Reciproc和Reciproc Blue系统对弯曲根管再治疗的性能比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=825f185e04da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923727, encodeId=16001923e27b5, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=第61届ASH：bluebird bio将展示其基因和细胞疗法的全新数据, objectType=article, longId=182555, objectId=4dc11825558b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dc11825558b, replyNumber=0, likeNumber=33, createdTime=2020-04-18, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dc11825558b, moduleTitle=第61届ASH：bluebird bio将展示其基因和细胞疗法的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dc11825558b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923723, encodeId=d6b51923e231b, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=J Endod：Micro-CT观察XP-endo Shaper, Reciproc Blue和ProTaper Universal NiTi对牙本质隐裂形成的, objectType=article, longId=163267, objectId=5cca16326e31, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cca16326e31, replyNumber=0, likeNumber=40, createdTime=2019-09-02, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cca16326e31, moduleTitle=J Endod：Micro-CT观察XP-endo Shaper, Reciproc Blue和ProTaper Universal NiTi对牙本质隐裂形成的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cca16326e31)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923725, encodeId=77561923e259e, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=Bluebirdβ-地中海贫血基因疗法Zynteglo，喜获欧盟有条件的上市许可, objectType=article, longId=167643, objectId=f63916e643e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f63916e643e2, replyNumber=0, likeNumber=41, createdTime=2020-01-08, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f63916e643e2, moduleTitle=Bluebirdβ-地中海贫血基因疗法Zynteglo，喜获欧盟有条件的上市许可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f63916e643e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923726, encodeId=938a1923e2609, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=拜耳预付款2.4亿美元收购BlueRock进行诱导多能干细胞治疗的研究, objectType=article, longId=177384, objectId=b3ec1e73841a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3ec1e73841a, replyNumber=0, likeNumber=37, createdTime=2019-11-11, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3ec1e73841a, moduleTitle=拜耳预付款2.4亿美元收购BlueRock进行诱导多能干细胞治疗的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3ec1e73841a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923717, encodeId=537d1923e175b, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=J Endod：Reciproc和Reciproc Blue镍钛往返锉在不同环境温度下的循环疲劳强度, objectType=article, longId=148161, objectId=6510148161c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6510148161c2, replyNumber=0, likeNumber=45, createdTime=2019-01-12, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6510148161c2, moduleTitle=J Endod：Reciproc和Reciproc Blue镍钛往返锉在不同环境温度下的循环疲劳强度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6510148161c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923724, encodeId=93191923e249b, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=欧洲CHMP推荐将Bluebird公司的基因疗法Zynteglo用于治疗输血依赖性β-地中海贫血, objectType=article, longId=163435, objectId=ce74163435a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce74163435a9, replyNumber=0, likeNumber=30, createdTime=2019-09-26, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce74163435a9, moduleTitle=欧洲CHMP推荐将Bluebird公司的基因疗法Zynteglo用于治疗输血依赖性β-地中海贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce74163435a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923720, encodeId=d6ab1923e2000, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=J Endod：不同根管入路角度对Reciproc和Reciproc Blue器械循环疲劳强度的影响, objectType=article, longId=155274, objectId=47ec1552e436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47ec1552e436, replyNumber=0, likeNumber=31, createdTime=2019-05-21, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47ec1552e436, moduleTitle=J Endod：不同根管入路角度对Reciproc和Reciproc Blue器械循环疲劳强度的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47ec1552e436)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923722, encodeId=a9a01923e22fe, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=J Endod：Reciproc Blue R25在无通道锉下的根管成型表现, objectType=article, longId=161118, objectId=8e0f161118e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e0f161118e5, replyNumber=0, likeNumber=23, createdTime=2019-07-29, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e0f161118e5, moduleTitle=J Endod：Reciproc Blue R25在无通道锉下的根管成型表现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e0f161118e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923718, encodeId=33f51923e1891, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=Clin Oral Investig：Reciproc Blue和Reciproc器械在模拟严重弯曲根尖内的循环疲劳强度, objectType=article, longId=149864, objectId=e77c14986459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e77c14986459, replyNumber=0, likeNumber=46, createdTime=2019-05-20, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e77c14986459, moduleTitle=Clin Oral Investig：Reciproc Blue和Reciproc器械在模拟严重弯曲根尖内的循环疲劳强度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e77c14986459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923719, encodeId=0c6f1923e1922, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=Clin Oral Investig：Reciproc Blue和Reciproc器械在严重弯曲根管内的疲劳强度测试, objectType=article, longId=149865, objectId=7891149865ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7891149865ca, replyNumber=0, likeNumber=38, createdTime=2019-01-26, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7891149865ca, moduleTitle=Clin Oral Investig：Reciproc Blue和Reciproc器械在严重弯曲根管内的疲劳强度测试, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7891149865ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1923721, encodeId=0f1c1923e21fd, content=<a href='/topic/show?id=093b353eed' target=_blank style='color:#2F92EE;'>#blue#</a>, objectTitle=基石药业合作伙伴Blueprint Medicines公布EXPLORER试验新近进展, objectType=article, longId=155888, objectId=52071558881f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52071558881f, replyNumber=0, likeNumber=24, createdTime=2019-10-19, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52071558881f, moduleTitle=基石药业合作伙伴Blueprint Medicines公布EXPLORER试验新近进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52071558881f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

blue

2020-05-29

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

Agendia在ASCO 2021上呈报创新性FLEX研究的数据，展示MammaPrint和BluePrint对广大类别患者群体的效用

2021-07-25

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

基因治疗出岔子了？蓝鸟(Bluebird Bio)暂停LentiGlobin基因疗法1/2、3期临床研究

2022-01-10

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

Bluebird突破性基因疗法Lenti-D申请上市！改善致死罕见病CALD患者长期生存结局

2021-01-12

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

全球改善结肠镜检查结果的口服药物Methylene Blue MMX，在欧洲获批

2021-01-10

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

罗氏与Blueprint达成17亿美元协议：合作开发RET抑制剂pralsetinib治疗肺癌和甲状腺癌

2021-06-19

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

吉利德Kite副总裁离职、拜耳CEO任期延长、BMS肿瘤研发首脑加入Blueprint……

2021-08-16

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

Blueprint的Ayvakit成为美国获批治疗罕见胃肠道间质瘤突变的靶向疗法

2020-03-26

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

J Endod：重复使用Reciproc Blue在根管再治疗中的循环疲劳强度

2020-05-02

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

J Endod：Reciproc和Reciproc Blue系统对弯曲根管再治疗的性能比较

2020-07-23

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

第61届ASH：bluebird bio将展示其基因和细胞疗法的全新数据

2020-04-18

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

J Endod：Micro-CT观察XP-endo Shaper, Reciproc Blue和ProTaper Universal NiTi对牙本质隐裂形成的

2019-09-02

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

Bluebirdβ-地中海贫血基因疗法Zynteglo，喜获欧盟有条件的上市许可

2020-01-08

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

拜耳预付款2.4亿美元收购BlueRock进行诱导多能干细胞治疗的研究

2019-11-11

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

J Endod：Reciproc和Reciproc Blue镍钛往返锉在不同环境温度下的循环疲劳强度

2019-01-12

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

欧洲CHMP推荐将Bluebird公司的基因疗法Zynteglo用于治疗输血依赖性β-地中海贫血

2019-09-26

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

J Endod：不同根管入路角度对Reciproc和Reciproc Blue器械循环疲劳强度的影响

2019-05-21

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

J Endod：Reciproc Blue R25在无通道锉下的根管成型表现

2019-07-29

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

Clin Oral Investig：Reciproc Blue和Reciproc器械在模拟严重弯曲根尖内的循环疲劳强度

2019-05-20

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

Clin Oral Investig：Reciproc Blue和Reciproc器械在严重弯曲根管内的疲劳强度测试

2019-01-26

ms4964546379600229 (审核中...)

前往app查看评论内容

#blue#

基石药业合作伙伴Blueprint Medicines公布EXPLORER试验新近进展

2019-10-19

科室
- - 订阅+
  - 更多科室
工具
服务